RM
Rockwell Medical, Inc.
RMTI · NASDAQ
$8.04 +3.94% (+$0.30)
1M +7.06%
Market Cap $31.7M
P/E Ratio -
Div. Yield -
ROE 14.03%
Bulios Fair Price
$6.85
14.8% downside
Current Price
$8.04
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RMTI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
82 /100
Cheap P/S 0.46x
P/FCF 20.61x
P/B 0.90x
Growth
32 /100
Declining Rev. growth 1.65%
Book val. growth 37.89%
EPS growth N/A
Profitability
11 /100
Weak Gross margin 17.71%
FCF margin 2.22%
Net margin 7.33%
Quality
15 /100
Poor ROIC 9.23%
Asset turnover 1.23x
ROE 14.03%
Debt
66 /100
Moderate Debt/Equity 0.40x
Int. coverage -3.48x
Current ratio 3.25x
Stability
16 /100
Unstable Beta 1.64x
Profitable years 0
Rev. volatility 28.98%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RMTI
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mark Strobeck
Employees
157
Headquarters
Wixom
Upcoming events
11 NOV
Earnings
Upcoming earnings report